Anti-amyloid monoclonal antibodies (mAbs)
- Disease-modifying drugs for early Alzheimer disease
- Require confirmed cerebral amyloid pathology
- Slow decline modestly; do not restore cognition
- ARIA-E/H is the defining toxicity
- MRI monitoring is required
- APOE ε4 increases ARIA risk
- Anticoagulation/bleeding risk needs caution
Class at a glance
- Disease-modifying drugs for early Alzheimer disease
Members / distinctions
- Require confirmed cerebral amyloid pathology
- Slow decline modestly; do not restore cognition
Safety / monitoring
- ARIA-E/H is the defining toxicity
- MRI monitoring is required
Safety distinctions
- APOE ε4 increases ARIA risk
- Anticoagulation/bleeding risk needs caution
Self-check
- What is the defining toxicity of anti-amyloid monoclonal antibodies?
ARIA-E/H.
- What monitoring is required for ARIA risk?
MRI monitoring.
Drugs in this class (2)
All drug classes · Open the interactive console ↗
